| Paris | |
| 135 | |
| Immunotherapies for the treatment of cancer and infectious diseases uzing viral vector technology with the goal of killing infected or cancerous cells. | |
| 1) TG4010 MUC-1 targeted immunotherapy for the treatment of non-small cell lung cancer (NSCLC) Phase 2b part of Phase 2b/3 TIME trial evaluating TG4010 with chemotherapy in first-line NSCLC completed and promising data presented; Phase 2 trials in combination with immune checkpoint inhibitors being planned. 2) Pexa-Vec oncolytic immunotherapy about to enter Phase 3 trial in first-line liver cancer with standard of care, sorafenib; several Phase 2 trials in various cancers underway and being planned, including in combination with immune checkpoint inhibitors. |
|
| CASTELLI Elisabetta | |
| www.transgene.fr | |
| TNG:FP |
Fiche créée le 10/04/2016 par 
Guillaume vue 8 fois.